Mikhail Blagosklonny Is Optimistic About Developing Cancer Therapies

Mikhail Blagosklonny, an oncologist, defined aging as “an exponential increase of the probability of age with death.” He insisted that all elderly humans and other mammals die from age-related diseases, resulting from natural causes. Age-related diseases such as cancer, cardiovascular diseases, diabetes, Alzheimer and Parkinson diseases, are bio markers of aging. Cellular aging is an MTOR-dependent process. The MTOR pathway is activated by growth factors, nutrients, hormones, oxygen and other conditions like obesity. MTOR, which is a sensing pathway in each cell, initiates certain functions of differentiated cells and cellular mass growth. MTOR causes cellular hyperfunctions and hypertrophy, which in turn alters homeostasis, leading to age-related diseases. Cancer slows aging through interventions such as calorie restrictions. However, rapamycin, a common cancer drug, is a strong inhibitor of MTOR, which delays cancer and slows aging. Visit ResearchGate to keep up to date with Mikhail’s latest work.

About Mikhail Blagosklonny

Mikhail Blagosklonny has spent many years studying cancer and aging. He advances his mission of developing innovative therapies through his current role at Roswell Park Cancer Institute as the Professor of oncology. The scientist pursued his degree at First Pavlov State Medical University. Later, he secured a job at New York Medical College in Valhalla where he worked as an associate professor of medicine. After a while, he joined Ordway Research Institute in Albany where he worked as a senior scientist until 2009 when he was appointed to serve as a professor at Roswell Park Cancer Institute. His diversified research interests revolve around cancer and targeted cancer therapies that ensure that normal cells are not damaged by cancer cells

The cancer therapy expert holds various editorial positions, including being the editor-in chief of Oncotarget and Cell Cycle. He is the co-founding editor of Aging, which ranks second among the leading journals in aging research. Mikhail Blagosklonny is also a founding member of 700 for science, a group consisting of commercialization experts, who work to create a support system of grassroots for innovative biotechnology developments. Over the years, he has published different works, including drugs and treatment for cancer and age-related diseases, increasing healthy lifespan by suppressing aging, the proximal cause of aging, and the restriction point of the cell cycle. View Mikhail’s profile on Google Scholar.

Lung Institute Restores Hope to Lung Disease Patients through Stem Cell Therapy

Chronic lung diseases can put one’s daily chores to an abrupt stop. The realization that you will no longer be enjoying doing your work due to shortness of breath can make you frustrated and even depressed. Luckily, Lung Institute offers stem cell therapy for lungs which will help you regain you pulmonary functions.

What is Stem Cell Therapy?

Every organism has essential building blocks of life known as stem cells. These cells have the ability to replicate and forming any tissue in the body. In adults, these cells are undifferentiated which make them capable of transforming their function to that of any other tissue in the body through plasticity process.

To perform stem cell therapy, the Lung Institute harvests stem cell from the patient’s body from either the blood tissue or the bone marrow. The ability of adult stem cells to form differentiated cells helps them promote healing once they are returned to the body. The stem cell therapy involves three steps; harvesting from either of the two body tissues, separating the sample cells, and returning the stem cells in the lungs where they automatically begin the healing process.

Types of Lung Conditions Treated Using Stem Cell Therapy

The Lung Institute uses stem cell therapy to deal with a number of lung conditions including;

About Lung Cancer Institute

The Lung Cancer Institute, founded in 2013 at Tampa, Florida, is the leading medical provider using regenerative therapy to treat lung diseases. Since its inception, the institute has successfully treated over 3000 patients suffering from lung diseases.

The institute’s success in treating lung diseases have made the receive worldwide recognition and have opened more centers in Scottsdale, Tennessee, Nashville, Texas, Dallas, Arizona, and Pittsburg, Pa. All their centers like Cedars-Sinai are world class which in combination with designated practices helps them provide quality help to lung disease patients.

For more information, visit the website at lunginstitute.com.